nodes	percent_of_prediction	percent_of_DWPC	metapath
Tapentadol—SLC6A4—attention deficit hyperactivity disorder	0.816	1	CbGaD
Tapentadol—SLC6A2—locus ceruleus—attention deficit hyperactivity disorder	0.0155	0.205	CbGeAlD
Tapentadol—SLC6A2—autonomic nervous system—attention deficit hyperactivity disorder	0.00821	0.109	CbGeAlD
Tapentadol—Phenylephrine—MAOA—attention deficit hyperactivity disorder	0.00416	1	CrCbGaD
Tapentadol—OPRD1—forebrain—attention deficit hyperactivity disorder	0.00383	0.0509	CbGeAlD
Tapentadol—OPRK1—forebrain—attention deficit hyperactivity disorder	0.00367	0.0488	CbGeAlD
Tapentadol—HTR3A—forebrain—attention deficit hyperactivity disorder	0.00285	0.0378	CbGeAlD
Tapentadol—OPRM1—forebrain—attention deficit hyperactivity disorder	0.00261	0.0347	CbGeAlD
Tapentadol—SLC6A4—forebrain—attention deficit hyperactivity disorder	0.00217	0.0289	CbGeAlD
Tapentadol—OPRD1—nervous system—attention deficit hyperactivity disorder	0.00208	0.0276	CbGeAlD
Tapentadol—OPRD1—central nervous system—attention deficit hyperactivity disorder	0.002	0.0266	CbGeAlD
Tapentadol—OPRK1—nervous system—attention deficit hyperactivity disorder	0.00199	0.0265	CbGeAlD
Tapentadol—OPRK1—central nervous system—attention deficit hyperactivity disorder	0.00192	0.0255	CbGeAlD
Tapentadol—SLC6A2—forebrain—attention deficit hyperactivity disorder	0.00191	0.0254	CbGeAlD
Tapentadol—OPRK1—cerebellum—attention deficit hyperactivity disorder	0.00188	0.0249	CbGeAlD
Tapentadol—OPRM1—midbrain—attention deficit hyperactivity disorder	0.00173	0.0229	CbGeAlD
Tapentadol—OPRD1—brain—attention deficit hyperactivity disorder	0.00159	0.0211	CbGeAlD
Tapentadol—HTR3A—nervous system—attention deficit hyperactivity disorder	0.00155	0.0205	CbGeAlD
Tapentadol—OPRK1—brain—attention deficit hyperactivity disorder	0.00152	0.0202	CbGeAlD
Tapentadol—HTR3A—central nervous system—attention deficit hyperactivity disorder	0.00149	0.0198	CbGeAlD
Tapentadol—SLC6A4—midbrain—attention deficit hyperactivity disorder	0.00144	0.0191	CbGeAlD
Tapentadol—OPRM1—nervous system—attention deficit hyperactivity disorder	0.00142	0.0188	CbGeAlD
Tapentadol—OPRM1—central nervous system—attention deficit hyperactivity disorder	0.00137	0.0181	CbGeAlD
Tapentadol—HTR3A—brain—attention deficit hyperactivity disorder	0.00118	0.0157	CbGeAlD
Tapentadol—CYP2C9—cardiovascular system—attention deficit hyperactivity disorder	0.00118	0.0157	CbGeAlD
Tapentadol—SLC6A4—nervous system—attention deficit hyperactivity disorder	0.00118	0.0157	CbGeAlD
Tapentadol—SLC6A4—central nervous system—attention deficit hyperactivity disorder	0.00114	0.0151	CbGeAlD
Tapentadol—OPRM1—brain—attention deficit hyperactivity disorder	0.00108	0.0144	CbGeAlD
Tapentadol—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.00105	0.0139	CbGeAlD
Tapentadol—SLC6A2—nervous system—attention deficit hyperactivity disorder	0.00104	0.0138	CbGeAlD
Tapentadol—SLC6A2—central nervous system—attention deficit hyperactivity disorder	0.001	0.0133	CbGeAlD
Tapentadol—SLC6A4—brain—attention deficit hyperactivity disorder	0.000902	0.012	CbGeAlD
Tapentadol—SLC6A2—brain—attention deficit hyperactivity disorder	0.000794	0.0105	CbGeAlD
Tapentadol—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.000569	0.00755	CbGeAlD
Tapentadol—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.000548	0.00727	CbGeAlD
Tapentadol—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.000535	0.00711	CbGeAlD
Tapentadol—CYP2D6—brain—attention deficit hyperactivity disorder	0.000435	0.00577	CbGeAlD
Tapentadol—OPRD1—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000277	0.00265	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000276	0.00264	CbGpPWpGaD
Tapentadol—OPRM1—G alpha (i) signalling events—HTR1B—attention deficit hyperactivity disorder	0.000272	0.0026	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.000272	0.0026	CbGpPWpGaD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000271	0.00259	CbGpPWpGaD
Tapentadol—OPRK1—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000269	0.00257	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.000267	0.00255	CbGpPWpGaD
Tapentadol—OPRK1—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.000264	0.00253	CbGpPWpGaD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000263	0.00251	CbGpPWpGaD
Tapentadol—OPRK1—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.000262	0.0025	CbGpPWpGaD
Tapentadol—OPRK1—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.000261	0.00249	CbGpPWpGaD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000258	0.00247	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000256	0.00244	CbGpPWpGaD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000255	0.00244	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000254	0.00243	CbGpPWpGaD
Tapentadol—OPRM1—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.000252	0.00241	CbGpPWpGaD
Tapentadol—UGT1A9—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000251	0.0024	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000251	0.0024	CbGpPWpGaD
Tapentadol—UGT1A9—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00025	0.00239	CbGpPWpGaD
Tapentadol—UGT1A9—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000248	0.00237	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000247	0.00236	CbGpPWpGaD
Tapentadol—OPRM1—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.000245	0.00234	CbGpPWpGaD
Tapentadol—OPRK1—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000243	0.00232	CbGpPWpGaD
Tapentadol—OPRM1—G alpha (i) signalling events—ADRA2A—attention deficit hyperactivity disorder	0.000241	0.0023	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000238	0.00227	CbGpPWpGaD
Tapentadol—OPRM1—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.000238	0.00227	CbGpPWpGaD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000237	0.00227	CbGpPWpGaD
Tapentadol—OPRM1—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000235	0.00224	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000234	0.00223	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00023	0.0022	CbGpPWpGaD
Tapentadol—OPRM1—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000227	0.00217	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000226	0.00216	CbGpPWpGaD
Tapentadol—HTR3A—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.000226	0.00216	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000224	0.00214	CbGpPWpGaD
Tapentadol—OPRM1—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.000223	0.00213	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000223	0.00213	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.000222	0.00212	CbGpPWpGaD
Tapentadol—OPRM1—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.000221	0.00212	CbGpPWpGaD
Tapentadol—SLC6A2—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.000221	0.00212	CbGpPWpGaD
Tapentadol—CYP2C19—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000221	0.00211	CbGpPWpGaD
Tapentadol—OPRM1—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.000221	0.00211	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000216	0.00207	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000212	0.00203	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000211	0.00202	CbGpPWpGaD
Tapentadol—HTR3A—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.00021	0.002	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000208	0.00199	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000207	0.00198	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000206	0.00197	CbGpPWpGaD
Tapentadol—OPRM1—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000205	0.00196	CbGpPWpGaD
Tapentadol—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000203	0.00194	CbGpPWpGaD
Tapentadol—CYP2C9—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000201	0.00193	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000201	0.00192	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.0002	0.00191	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000197	0.00188	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.000195	0.00186	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000195	0.00186	CbGpPWpGaD
Tapentadol—OPRD1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.000194	0.00186	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.000194	0.00186	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000192	0.00184	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000191	0.00183	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000189	0.00181	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000188	0.0018	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000188	0.0018	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000185	0.00177	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000182	0.00174	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000181	0.00173	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000181	0.00173	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000176	0.00168	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.000175	0.00168	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000172	0.00165	CbGpPWpGaD
Tapentadol—OPRK1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00017	0.00163	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00017	0.00163	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000169	0.00162	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000168	0.00161	CbGpPWpGaD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000166	0.00159	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000165	0.00158	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.000165	0.00157	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000159	0.00152	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000157	0.0015	CbGpPWpGaD
Tapentadol—UGT1A9—PPARA activates gene expression—EP300—attention deficit hyperactivity disorder	0.000154	0.00147	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000154	0.00147	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000153	0.00146	CbGpPWpGaD
Tapentadol—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—attention deficit hyperactivity disorder	0.000151	0.00144	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000148	0.00142	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.000148	0.00142	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000146	0.00139	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000146	0.00139	CbGpPWpGaD
Tapentadol—OPRM1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.000144	0.00138	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.000144	0.00138	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000144	0.00137	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000142	0.00136	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.000141	0.00135	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000139	0.00133	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000134	0.00128	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000132	0.00126	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00013	0.00125	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000127	0.00121	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000127	0.00121	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000126	0.0012	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000126	0.0012	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000125	0.0012	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000123	0.00118	CbGpPWpGaD
Tapentadol—CYP2C19—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000118	0.00113	CbGpPWpGaD
Tapentadol—CYP2C19—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000117	0.00112	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000117	0.00112	CbGpPWpGaD
Tapentadol—CYP2C19—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000117	0.00111	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000116	0.00111	CbGpPWpGaD
Tapentadol—SLC6A4—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	0.000115	0.0011	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000114	0.00109	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000114	0.00109	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000113	0.00108	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000113	0.00108	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000112	0.00108	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000111	0.00106	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000111	0.00106	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000111	0.00106	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00011	0.00105	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00011	0.00105	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000109	0.00104	CbGpPWpGaD
Tapentadol—CYP2D6—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000109	0.00104	CbGpPWpGaD
Tapentadol—CYP2D6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000108	0.00103	CbGpPWpGaD
Tapentadol—CYP2C9—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000108	0.00103	CbGpPWpGaD
Tapentadol—CYP2D6—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000107	0.00102	CbGpPWpGaD
Tapentadol—CYP2C9—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000107	0.00102	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000106	0.00102	CbGpPWpGaD
Tapentadol—CYP2C9—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000106	0.00102	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000106	0.00101	CbGpPWpGaD
Tapentadol—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—attention deficit hyperactivity disorder	0.000104	0.000994	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000103	0.000983	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000103	0.000981	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000102	0.000978	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000102	0.000977	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000101	0.000964	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	9.99e-05	0.000955	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	9.96e-05	0.000952	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	9.95e-05	0.000951	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	9.91e-05	0.000947	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	9.78e-05	0.000935	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	9.74e-05	0.000932	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	9.74e-05	0.000931	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	9.66e-05	0.000924	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	9.62e-05	0.00092	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	9.56e-05	0.000914	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	9.39e-05	0.000897	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	9.3e-05	0.000889	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	9.29e-05	0.000888	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	9.28e-05	0.000887	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	9e-05	0.00086	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	8.96e-05	0.000857	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	8.84e-05	0.000846	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	8.74e-05	0.000835	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—TPH2—attention deficit hyperactivity disorder	8.73e-05	0.000835	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—CACNB2—attention deficit hyperactivity disorder	8.73e-05	0.000835	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	8.65e-05	0.000827	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—DPYD—attention deficit hyperactivity disorder	8.59e-05	0.000821	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	8.45e-05	0.000808	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	8.41e-05	0.000804	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	8.37e-05	0.000801	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	8.24e-05	0.000787	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	8.23e-05	0.000787	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	8.14e-05	0.000778	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	8.13e-05	0.000777	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	8.08e-05	0.000772	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—CACNA1C—attention deficit hyperactivity disorder	7.99e-05	0.000764	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	7.85e-05	0.000751	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	7.7e-05	0.000736	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	7.61e-05	0.000727	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	7.57e-05	0.000724	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	7.48e-05	0.000715	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	7.38e-05	0.000706	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	7.16e-05	0.000684	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—TPH2—attention deficit hyperactivity disorder	7.1e-05	0.000678	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—CACNB2—attention deficit hyperactivity disorder	7.1e-05	0.000678	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—SNAP25—attention deficit hyperactivity disorder	6.98e-05	0.000667	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—DPYD—attention deficit hyperactivity disorder	6.98e-05	0.000667	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	6.88e-05	0.000658	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	6.75e-05	0.000646	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	6.73e-05	0.000644	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—ADRA2A—attention deficit hyperactivity disorder	6.65e-05	0.000635	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	6.5e-05	0.000621	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—CACNA1C—attention deficit hyperactivity disorder	6.49e-05	0.000621	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	6.28e-05	0.0006	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	6.26e-05	0.000598	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	6.06e-05	0.00058	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	5.96e-05	0.00057	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	5.9e-05	0.000564	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.89e-05	0.000563	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	5.71e-05	0.000546	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	5.7e-05	0.000545	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—SNAP25—attention deficit hyperactivity disorder	5.67e-05	0.000542	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	5.49e-05	0.000525	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.48e-05	0.000524	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—ADRA2A—attention deficit hyperactivity disorder	5.4e-05	0.000516	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	5.32e-05	0.000508	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	5.3e-05	0.000507	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—COMT—attention deficit hyperactivity disorder	5.29e-05	0.000506	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—MAOA—attention deficit hyperactivity disorder	5.25e-05	0.000502	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	5.22e-05	0.0005	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.16e-05	0.000493	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.99e-05	0.000477	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ADRA2C—attention deficit hyperactivity disorder	4.83e-05	0.000462	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	4.82e-05	0.000461	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.81e-05	0.00046	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.64e-05	0.000443	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.49e-05	0.00043	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	4.44e-05	0.000425	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.42e-05	0.000422	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ADRA2C—attention deficit hyperactivity disorder	4.41e-05	0.000421	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.36e-05	0.000417	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—COMT—attention deficit hyperactivity disorder	4.3e-05	0.000411	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—MAOA—attention deficit hyperactivity disorder	4.27e-05	0.000408	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	4.14e-05	0.000396	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.06e-05	0.000388	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.84e-05	0.000367	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.37e-05	0.000322	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—TPH2—attention deficit hyperactivity disorder	3.34e-05	0.000319	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CACNB2—attention deficit hyperactivity disorder	3.34e-05	0.000319	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—DPYD—attention deficit hyperactivity disorder	3.28e-05	0.000314	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	3.07e-05	0.000293	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	3.07e-05	0.000293	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.05e-05	0.000292	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CACNB2—attention deficit hyperactivity disorder	3.04e-05	0.000291	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—TPH2—attention deficit hyperactivity disorder	3.04e-05	0.000291	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	3.02e-05	0.000289	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—DPYD—attention deficit hyperactivity disorder	2.99e-05	0.000286	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.85e-05	0.000272	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.81e-05	0.000268	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.78e-05	0.000266	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.67e-05	0.000255	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.54e-05	0.000243	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.45e-05	0.000234	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.43e-05	0.000232	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.33e-05	0.000223	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.31e-05	0.000221	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—EP300—attention deficit hyperactivity disorder	2.27e-05	0.000217	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.03e-05	0.000194	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—COMT—attention deficit hyperactivity disorder	2.02e-05	0.000193	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—MAOA—attention deficit hyperactivity disorder	2.01e-05	0.000192	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	1.95e-05	0.000186	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	1.86e-05	0.000178	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	1.85e-05	0.000176	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—EP300—attention deficit hyperactivity disorder	1.84e-05	0.000176	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—COMT—attention deficit hyperactivity disorder	1.84e-05	0.000176	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—MAOA—attention deficit hyperactivity disorder	1.83e-05	0.000175	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.78e-05	0.000171	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	1.77e-05	0.00017	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.51e-05	0.000144	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—EP300—attention deficit hyperactivity disorder	8.67e-06	8.28e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	7.97e-06	7.62e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—EP300—attention deficit hyperactivity disorder	7.9e-06	7.55e-05	CbGpPWpGaD
